# Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Source: https://onco.cc/trials/nct07620574/  
OnCo record `nct07620574` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cabozantinib, zanzalintinib, atezolizumab, nivolumab and other drugs in colorectal cancer, run by Exelixis, now recruiting.

## Summary

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study is a phase 3, interventional study registered as NCT07620574 by Exelixis, with a registry enrolment figure of 5000 participants, started 2026-07-30 and due to reach its primary completion in 2030-05-31. Interventions recorded: Cabozantinib; Zanzalintinib; Atezolizumab; Nivolumab; Abiraterone; Prednisone; Enzalutamide. Conditions listed: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer. Primary outcome: Number of Participants With Treatment Emergent Adverse Events (TEAEs). Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07620574
- Phase: 3
- Setting: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- Sponsor: Exelixis
- Enrolled: 5000

## Sources

- ClinicalTrials.gov NCT07620574: https://clinicaltrials.gov/study/NCT07620574

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Prednisone](https://onco.cc/drugs/prednisone/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Exelixis](https://onco.cc/companies/exelixis/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07620574.json